Literature DB >> 3856479

Coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon.

J Mirro, D Kalwinsky, J Whisnant, P Weck, C Chesney, S Murphy.   

Abstract

Seven patients with myeloblastic leukemia were treated for 10 days with high-dose (15 or 30 million units/m2/day), human lymphoblastoid interferon (Wellferon) by continuous iv infusion. All patients developed prolonged activated partial thromboplastin time, and four developed prolonged prothrombin time. Factor assays demonstrated low levels of II, VII, IX, X, and XII. Coagulation abnormalities improved after discontinuation of interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856479

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

Review 1.  Safety evaluation of biotechnology products.

Authors:  G Zbinden
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

Review 2.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 3.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.